150 related articles for article (PubMed ID: 3169114)
1. The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment.
Schulz M; Schmoldt A; Donn F; Becker H
Eur J Clin Pharmacol; 1988; 34(6):633-6. PubMed ID: 3169114
[TBL] [Abstract][Full Text] [Related]
2. Single and multiple dose pharmacokinetic evaluation of flutamide in normal geriatric volunteers.
Radwanski E; Perentesis G; Symchowicz S; Zampaglione N
J Clin Pharmacol; 1989 Jun; 29(6):554-8. PubMed ID: 2754024
[TBL] [Abstract][Full Text] [Related]
3. Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide.
Bélanger A; Giasson M; Couture J; Dupont A; Cusan L; Labrie F
Prostate; 1988; 12(1):79-84. PubMed ID: 3279409
[TBL] [Abstract][Full Text] [Related]
4. Determination of 2-hydroxyflutamide in human plasma by high-performance liquid chromatography and its application to pharmacokinetic studies.
Niopas I; Daftsios AC
J Chromatogr B Biomed Sci Appl; 2001 Aug; 759(1):179-83. PubMed ID: 11499624
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of flutamide in patients with renal insufficiency.
Anjum S; Swan SK; Lambrecht LJ; Radwanski E; Cutler DL; Affrime MB; Halstenson CE
Br J Clin Pharmacol; 1999 Jan; 47(1):43-7. PubMed ID: 10073738
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of the anti-androgenic drug flutamide in healthy stallions.
Mendoza FJ; Serrano-Rodriguez JM; Buzon-Cuevas A; Perez-Ecija A
Vet J; 2017 Jun; 224():50-54. PubMed ID: 28697876
[TBL] [Abstract][Full Text] [Related]
7. Steady-state hydroxyflutamide plasma levels after the administration of two dosage forms of flutamide.
Asade RH; Prizont L; Muiño JP; Tessler J
Cancer Chemother Pharmacol; 1991; 27(5):401-5. PubMed ID: 1999002
[TBL] [Abstract][Full Text] [Related]
8. Flutamide metabolism in four different species in vitro and identification of flutamide metabolites in human patient urine by high performance liquid chromatography/tandem mass spectrometry.
Tevell A; Lennernäs H; Jönsson M; Norlin M; Lennernäs B; Bondesson U; Hedeland M
Drug Metab Dispos; 2006 Jun; 34(6):984-92. PubMed ID: 16540588
[TBL] [Abstract][Full Text] [Related]
9. Hydroxypropyl-beta-cyclodextrin-flutamide inclusion complex. II. Oral and intravenous pharmacokinetics of flutamide in the rat.
Zuo Z; Tam YK; Diakur J; Wiebe LI
J Pharm Pharm Sci; 2002; 5(3):292-8. PubMed ID: 12553899
[TBL] [Abstract][Full Text] [Related]
10. [Phase I study of flutamide, a nonsteroidal antiandrogen, in patients with prostatic cancer].
Aso Y; Akaza H; Koiso K; Kumamoto Y; Kawai T; Origasa S; Hosaka M; Yamanaka H; Shimazaki J; Fuse H
Hinyokika Kiyo; 1993 Apr; 39(4):381-9. PubMed ID: 8503338
[TBL] [Abstract][Full Text] [Related]
11. Bioequivalence evaluation of two flutamide preparations in healthy female subjects.
Doser K; Guserle R; Kramer R; Laufer S; Lichtenberger K
Arzneimittelforschung; 1997 Feb; 47(2):213-7. PubMed ID: 9079242
[TBL] [Abstract][Full Text] [Related]
12. Detection of a new N-oxidized metabolite of flutamide, N-[4-nitro-3-(trifluoromethyl)phenyl]hydroxylamine, in human liver microsomes and urine of prostate cancer patients.
Goda R; Nagai D; Akiyama Y; Nishikawa K; Ikemoto I; Aizawa Y; Nagata K; Yamazoe Y
Drug Metab Dispos; 2006 May; 34(5):828-35. PubMed ID: 16507648
[TBL] [Abstract][Full Text] [Related]
13. Flutamide-induced hepatic dysfunction in relation to steady-state plasma concentrations of flutamide and its metabolites.
Aizawa Y; Ikemoto I; Kishimoto K; Wada T; Yamazaki H; Ohishi Y; Kiyota H; Furuta N; Suzuki H; Ueda M
Mol Cell Biochem; 2003 Oct; 252(1-2):149-56. PubMed ID: 14577588
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of an injectable modified-release 2-hydroxyflutamide formulation in the human prostate gland using a semiphysiologically based biopharmaceutical model.
Sjögren E; Tammela TL; Lennernäs B; Taari K; Isotalo T; Malmsten LÅ; Axén N; Lennernäs H
Mol Pharm; 2014 Sep; 11(9):3097-111. PubMed ID: 25055161
[TBL] [Abstract][Full Text] [Related]
15. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
Furr BJ; Tucker H
Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
[TBL] [Abstract][Full Text] [Related]
16. An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer.
Tammela TL; Häggman M; Ladjevardi S; Taari K; Isotalo T; Lennernäs H; Weis J; von Below C; Wassberg C; Lennernäs B; Tolf A; Axén N; Gölander CG; Ahlström H
J Urol; 2017 Dec; 198(6):1333-1339. PubMed ID: 28736321
[TBL] [Abstract][Full Text] [Related]
17. Disposition of a new, nonsteroid, antiandrogen, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro-m-propionotoluidide (Flutamide), in men following a single oral 200 mg dose.
Katchen B; Buxbaum S
J Clin Endocrinol Metab; 1975 Aug; 41(2):373-9. PubMed ID: 1159048
[TBL] [Abstract][Full Text] [Related]
18. Bioactivation of flutamide metabolites by human liver microsomes.
Kang P; Dalvie D; Smith E; Zhou S; Deese A; Nieman JA
Drug Metab Dispos; 2008 Jul; 36(7):1425-37. PubMed ID: 18411402
[TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing.
Cockshott ID; Cooper KJ; Sweetmore DS; Blacklock NJ; Denis L
Eur Urol; 1990; 18 Suppl 3():10-7. PubMed ID: 2094606
[TBL] [Abstract][Full Text] [Related]
20. Identification of the Additional Mitochondrial Liabilities of 2-Hydroxyflutamide When Compared With its Parent Compound, Flutamide in HepG2 Cells.
Ball AL; Kamalian L; Alfirevic A; Lyon JJ; Chadwick AE
Toxicol Sci; 2016 Oct; 153(2):341-51. PubMed ID: 27413113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
